Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of QVA149 in COPD
NCT01610037Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2012
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of indacaterol, glycopyrrolate metered dose inhaler in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Oct 2012; status: completed.
02
Drugs
indacaterolglycopyrrolate metered dose inhaler
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01610037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01610037.